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themost commonlyused. Aminority of studies tested for genetic abnormalities (12), soluble interleukin-2 recep-
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(HLH-94/HLH-2004) or doxorubicin-based (CHOP) initial therapy regimens. Allogeneic hematopoietic cell ther-
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from 20 to 88%. Developing adult-speciﬁc diagnostic criteria based on widely evaluable features of secondary
HPS/HLH and establishing standard initial therapies are priorities for future research.
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Adults1. Introduction
Hemophagocytic syndromes (HPSs) are rare, life-threatening
conditions characterized by overstimulation of the immune system
leading to systemic inﬂammation, hypercytokinemia and multi-organ
failure [1]. They are broadly divided into primary hemophagocytic
lymphohistiocytosis (HLH) and secondary hemophagocytic syndromes
[2]. Primary HLH is caused by geneticmutations impairing the cytotoxic
function of natural killer (NK) and cytotoxic T cells and typically present
in infancy and childhood. Primary HLH includes familial HLH (fHLH),
where patients have autosomal recessive mutations in Perforin
(PRF1), MUNC 13-4 (UNC13D), MUNC 19-2 (STXBP2), and Syntaxin
11 (STX11) [3–7]. Primary HLH also includes other inherited immuno-
deﬁciency syndromes such as Chédiak–Higashi syndrome, Griscelli
syndrome, and type II Hermansky–Pudlak syndrome [8]. Secondary
hemophagocytic syndromes generally affect adolescents and adults
and are not associated with known genetic defects, although rare
cases of fHLH have been reported beyond age 70 [9–11].niversity of British Columbia,
5Z 1M9, Canada. Tel 1 604 875
. This is an open access article underIn secondary, or reactive, HPS there is often an associated “predis-
posing condition” causing immune dysregulation, such as malignancy
(particularly lymphoma), immunodeﬁciency, or autoimmune disease,
and/or a “trigger”, most commonly infection such as Epstein–Barr
virus (EBV) [8]. In some cases, an associated disease process is not
identiﬁed [12]. HPS may also be referred to as macrophage activation
syndrome (MAS) when it occurs in patients with autoimmune disease
such as juvenile idiopathic arthritis (JIA), adult-onset Still's disease
(AOSD) and systemic lupus erythematosus (SLE) [13,14]. The patholog-
ic immune activation that characterizes HPS/HLH can be difﬁcult to
distinguish from physiologic macrophage activation. For example, nei-
ther the presence [15,16], nor amount of hemophagocytosis on bone
marrow biopsies is speciﬁc for HPS/HLH [17]. Historical terms used to
describe HPS are summarized in Table 1.
The modern conceptualization of adult HPS/HLH is derived largely
from observations of familial HLH in children followed by the discovery
of causative genetic abnormalities. Diagnostic criteria speciﬁc for adult
HPS have not been established, and diagnosis is largely based on the
Histiocyte Society's HLH-94 or 2004 (Table 2) pediatric diagnostic
criteria [12]. A number of described manifestations of adult HPS, such
as transaminitis, coagulopathy, elevated LDH, rash, hyponatremia,
elevated CRP, and neurologic involvement (which is described in one
small study), are not included in these criteria [18–22]. As withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Nomenclature and diagnostic criteria of hemophagocytic syndromes: historical overview.
▪ 1939 — Histiocytic medullary reticulocytosis [85]
▪ 1952 — Familial hemophagocytic reticulocytosis [86]
▪ 1966 — Malignant histiocytosis described; majority of cases subsequently
re-classiﬁed as anaplastic large cell lymphoma [87]
▪ 1979 — Virus-associated hemophagocytic syndrome (VAHS) [88]
▪ 1980 — Cytophagic histiocytic panniculitis [89]
▪ 1983 — Familial hemophagocytic lymphohistiocytosis [90]
▪ 1991 — Histiocyte Society diagnostic criteria for HLH developed [52]
▪ 1993 — Macrophage activation syndrome (children with inﬂammatory joint
disease) [91]
▪ 1999 — Perforin gene mutation identiﬁed [3]
▪ 2004 — Histiocyte Society diagnostic criteria updated [12]
412 A. Hayden et al. / Blood Reviews 30 (2016) 411–420diagnosis, treatment protocols for adult HPS/HLH are often extrapo-
lated from the pediatric HLH-94 and HLH-2004 protocols. These are
etoposide-based regimens containing corticosteroids, cyclosporine
A, intravenous immunoglobulins (IVIG), intrathecal therapy, and
liberal use of allogeneic stem cell transplant in higher risk patients
[23]. How well these treatment protocols apply to adults is poorly
understood.
To date, the literature on adult HPS/HLH consists largely of retro-
spective studies, often conﬁned to a single center or geographic region.
Most literature reviews are narrative [24–26], although systematic
reviews have been done for speciﬁc types of HPS/HLH such as HPS asso-
ciated with zoonotic infections [27–29]. We conducted a systematic
search to identify the extent of existing literature on HPS/HLH, an area
with considerable clinical and methodological heterogeneity. We
analyzed the ﬁndings using scoping review methodology. Scoping
reviews are similar to systematic reviews in terms of searching the
literature in a reproducible manner, but the aim of a scoping review is
generally to address a broad area or topic (as opposed to a narrowly
deﬁned question) and scoping reviews do not emphasize the quality
or methodology of included studies (as opposed to the stringent
assessment of clinical heterogeneity, methodology and quality in
systematic reviews) [30–32]. The aims of this systematic scoping review
were to:
1. provide an overview of existing adult HPS/HLH literature and
publication trends over time
2. describe established patterns and emerging trends in diagnosis and
treatment of adult HPS/HLH
3. propose priorities for future researchTable 2
Histiocyte Society HLH-2004 diagnostic criteria.
The diagnosis HLH requires that either 1 or 2 below are fulﬁlled:
(1) A molecular diagnosis consistent with HLH
(2) Diagnostic criteria for HLH fulﬁlled (5 out of the 8 criteria below)
(A) Initial diagnostic criteria
Fever
Splenomegaly
Cytopenias (affecting ≥2 of 3 lineages in the peripheral blood):
Hemoglobin b90 g/L (in infants b 4 weeks: hemoglobin b 100 g/L)
Platelets b 100 × 109/L
Neutrophils b 1.0 × 109/L
Hypertriglyceridemia and/or hypoﬁbrinogenemia:
Fasting triglycerides ≥ 3.0 mmol/L (i.e., ≥265 mg/dL)
Fibrinogen ≤ 1.5 g/L
Hemophagocytosis in bone marrow or spleen or lymph nodes
(B) New diagnostic criteria
Low or absent NK-cell activity
Ferritin ≥ 500 mg/L
Soluble CD25 (i.e., soluble IL-2 receptor) ≥2400 U/mL2. Methods
2.1. Search strategy
A comprehensive literature search was performed using the
databases Ovid Medline, Embase, and PubMed. The aim was to
maximize sensitivity for ﬁnding published, peer-reviewed studies of
adult HPS/HLH. Our search terms and medical subject headings
(MeSH) were: h(a)emophagocytic syndrome(s) OR h(a)emophagocytic
lymphohistiocytosis OR h(a)ematophagic histiocytosis OR macrophage ac-
tivation syndrome(s) OR cytophagic histiocytic panniculitis AND adult(s)
AND English (language) AND humans.Weexcluded child(ren) as a search
term and limited results to publication years 1975–2015. As extended
search techniques, PubMed and the Web of Science were used to
identify more recent articles as well as the most highly cited publica-
tions in the ﬁeld. Final updated searches were performed on September
3, 2015. Results were screened based on titles and abstracts to deter-
mine suitability for inclusion in this scoping review. “Gray literature”
such as theses were not included; most conference proceedings were
excluded except for two abstractswith important information on genet-
ic testing and outcomes after Hematopoetic Cell Transplant (HCT).
Details of the search strategy can be found in Supplementary Appendi-
ces 1, 2 and 3.2.2. Study selection and data collection
All articles that addressed the topic of HPS/HLH in adults (deﬁned as
age N 15 years) were screened by full text review. English language
articles with 10 or more original cases were selected for the scoping re-
view. The minimum of 10 cases was arbitrarily chosen to identify larger
studies. Data extraction was done by one investigator, checked by two
others, and included: ﬁrst author, journal, year of publication, country
of origin, type and design of study, number of patients included, inclu-
sion/exclusion criteria, demographic features, diagnostic criteria, details
on genetic testing, associated conditions, clinicopathologic features,
treatment, outcomes, and additional notes on the study.3. Results
The search strategy gathered 2492 articles and upon manual review
and cross-referencing (35) and eliminating duplicates (932), the total
number of unique articles on adult HPS/HLH identiﬁed was 1590
(Fig. 1). Through the last updated search on Sept. 3, 2015, 552 new arti-
cles were identiﬁed onWeb of Science, some of which overlapped with
previously identiﬁed articles.
82 articles included 10 ormore adults with HPS/HLH andwere eligi-
ble for this review (see Supplementary Appendix 4 for complete list). 72
articles were retrospective and 10 were prospective [33–42]. Two of
these prospective studies were clinical trials [33,34], three examined
incidence and natural history of secondary HPS, and ﬁve investigated
cytokine/biomarker signiﬁcance. Fig. 2 illustrates the dramatic increase
in the number of articles published per year on this subject; 56 of the 82
articles included were published in the past ten years. 44 articles were
from Asian institutions (Fig. 3).
Three studies that did not strictly meet the inclusion criteria were
still included because they were of special interest:
1) A study of 9 patientswithHPS because itwas oneof the fewprospec-
tive studies [35].
2) An abstract of 10 patients who underwent allogeneic HCT in
Cincinnati because it was one of the few studies reporting genetic
abnormalities in adults [43].
3) An abstract of 19 patients from Cincinnati, with overlapping patients
from the above study, because it reported outcomes after HCT [44].
Fig. 1. PRISMA ﬂowchart of study selection process.
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A recent systematic review combined results fromnumerous studies
to gather information on the clinical presentation and treatment of HLH
in adults [24]. For example, they reported amortality rate of 41% in 1109
adults pooled from 13 articles. However, it is unlikely that these truly
represent 1109 unique patients, as many patient series in the literature
have been reported numerous times in different publications. For
example, two of the 13 articles cited are from the same French center
with overlapping study periods [1,45]. Investigators from this French
group have published numerous important articles which describe dif-
ferent aspects of HPS in overlapping cohorts of patients [1,18,39,45–
49]. A full list of studies with patients that were deﬁnitely or poten-
tially described in more than one study is included in Supplementary
Appendix 5.Fig. 2. Number of articles published on HLH in adults 1979–2015.3.2. Epidemiology
There is limited data on incidence of HPS/HLH, particularly in adult
populations. A nationwide survey in Japan evaluating pediatric and
adult cases reported annual incidence at 1 per 800,000 [50]. Pediatric
HLH diagnosis has been approximated to be 1 case per 3000 inpatient
admissions, and incidence per live birth has been estimated to be 1–6/
300,000 [25,26]. A single-center retrospective Swedish study reportedFig. 3. Countries publishing on HLH with a cohort of ≥10 cases.
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[51]. The majority of articles included in this review originated
from Asia and particularly Japan (see Fig. 3). Whether this suggests a
higher incidence of HPS/HLH in this region, geographic variations in
EBV-associated HPS/HLH, greater academic interest in HPS/HLH, or
some combination thereof, is not clear. Three single-center studies
prospectively examined the incidence and natural history of HPS associ-
ated with speciﬁc conditions in consecutive patients: 32 of 343 pts with
AML [38], 12 of 20 patients with sepsis and thrombocytopenia on
mechanical ventilation [35] and 9 of 25 pts with inﬂuenza A [37].
3.3. Diagnostic criteria
We reviewed the diagnostic criteria applied by each of the 82 articles
in order to understand the consistency of HPS/HLH diagnosis in the
literature and how this has changed over time (Table 1). Six distinct di-
agnostic criteria have been used (summarized in Table 3); of these, the
Histiocyte Society's criteria are by far the most commonly used.
3.3.1. Studies using Histiocyte Society diagnostic criteria
The Histiocyte Society published diagnostic criteria in 1991, which
were used for the pediatric HLH-94 trial [52]. 1 survey and 3 other
articles used these diagnostic criteria [50,53–55]. Updated criteria,
used for the HLH-2004 study, were published in 2007. 36 of the 54
articles (67%) published since 2007 in this review used HLH-2004 and
6 usedmodiﬁed HLH-2004 criteria.Many investigators have recognized
the limitations of applying the pediatric HLH-2004 diagnostic criteria to
adults [17,18,25,46]. These limitations fall into three categories:
1) Limitations of molecular testing: Only 12 of 54 studies performed
genetic testing on at least one patient (Table 4). [10,22,33,34,43,
56–62] The largest study of genetic mutations in adults from Cincin-
nati Children's HospitalMedical Center (CCHMC) reported that 25 of
175 (15%) adults had amutation in PRF1,MUNC13-4 or STXBP2 [10].
Patient samples in this study were referred from all over North
America and so the true denominator of adultswithHPS/HLH cannot
be ascertained. Moreover, classical familial HLH is caused by homo-
zygous mutations in autosomal recessive genes; heterozygous allele
mutations and mutations of unknown functional signiﬁcance are
included inmany of these reports, and the signiﬁcance of these ﬁnd-
ings is incompletely understood.
2) Accessibility of sIL2r and NK function:Many articles stated that sIL2r
and NK function were not readily available at the study center. OnlyTable 3
Summary of main HLH diagnostic criteria used in literature.
HLH diagnostic criteria
Diagnostic feature HLH 1994 Tsuda 1997 Imashu
Molecular diagnosis – – –
Fever X X X
Splenomegaly X X X
Cytopenia(s) X X X
Hypertriglyceridemia X X –
Hypoﬁbrinogenemia X X –
Hemophagocytosis X X X
Coagulopathy – X –
Decreased NK activity – – –
Serum ferritin – – X
Increased LDH – – X
Increased sIL2r – – –
Increased AST – – –
Immunosuppression – – –
Engraftment failure post HCT – – –
Number of studies using criteria* 4 7 4
Notes All required
for diagnosis
All required
for diagnosis
All requ
for diag
*Not all papers are included as some did not specify details of diagnostic criteria applied.11 of 54 studies published since 2007 commented on testing for
sIL2r [17,19,22,34,37,58,59,61–64], and 11 studies commented on
NK function testing [10,17,19,22,43,57–59,62,64,65]. Most of these
studies reported testing in a small proportion of patients. sIL2r was
elevated in 148 of 161 patients tested (91.9%) and 41 of 72 (56.9%)
patients tested had absent or low NK cell activity.
3) Different presenting features in adults: A number of studies
comment on how hemophagocytic syndromes, particularly re-
active hemophagocytic syndromes, may present in adults with
manifestations not included in the HLH-2004 criteria, such as
elevated aspartate transaminase (AST) [18] or lactate dehydro-
genase (LDH) [66]3.3.2. Studies using other diagnostic criteria
Prior to 2007, all articles in this review required pathologic evidence
of hemophagocytosis on bone marrow biopsy, aspirate, lymph node,
spleen or liver, in addition to typical clinical features, which often in-
cluded but did not require fever, cytopenias and splenomegaly. In
total, 14 articles required histologic evidence of hemophagocytosis but
no other speciﬁc diagnostic criterion. 8 of 11 articles published before
2000 did not use any standardized diagnostic criteria. In 1997, Tsuda
et al. and Imashuku et al. each published modiﬁed criteria which built
on the HLH-94 diagnostic criteria (Table 3) [20,66]. These criteria
were employed by 11 articles combined (7 and 4 respectively).
One study developed novel diagnostic criteria for diagnosis of HLH
in AML patients [38]. Emmenegger et al. proposed a ferritin value of
≥10,000 μg/L and/or morphologic evidence of hemophagocytosis as
a screening strategy [14,67]. Takagi et al. created and applied
novel criteria for Hematopoeitic Stem Cell Transplantation-related
Hemophagocytic Syndrome (HCT-HPS) comprised of 2 major and 4
minor criteria which excluded cytopenias given the post-HCT context
[68].
Fardet et al. proposed a novel set of diagnostic criteria for reactive
HPS, the HScore, which is based on data from 162 patients and the
ﬁrst to be validated in an adult population [18]. Nineweighted variables
were considered: 3 clinical [known underlying immunosuppression
(such as HIV or chronic use of immunosuppressive medications),
fever, organomegaly], 5 biologic (triglyceride, ferritin, aspartate trans-
aminase (AST), ﬁbrinogen, cytopenia), and 1 cytologic (HPS features
on BM aspirate). sIL2r levels and NK cell activity were not included
due to concerns about accessibility.ku 1997 HLH 2004 Takagi 2009 Fardet 2014
X – –
X X X
X X X
X – X
X – X
X – X
X X X
– – X
X – –
X X X
– X –
X – –
– – X
– – X
– X –
42 1 1
ired
nosis
5/8 or molecular
diagnosis
2 major or 1 major
and 4 minor criteria
Probability based
on HScore
Table 4
Details of genetic testing done in 12 studies.
Ref. Center Period of study No patients tested No. genetic defects (%) Genetic mutations/variants detected
Zhang [10] CCHMC ND 175 27 (15%) 18 PRF1, 7 MUNC12-4 and 2 STXBP2
17 monoallelic, 10 biallelic
Chandrakasan [43] CCHMC 2004–12 10 4 (40) 2 PRF1, 1 MUNC 13-4, 1 XIAP
Otrock [58] WUMC 2003–14 7 0 (0) N/A
Otrock [59] WUMC 2003–14 1 0 (0) N/A
Huasong [60] Jinan,
China
2004–13 21 0 (0) N/A
Wang [33] BFH 2010–11 40 0 (0) N/A
Wang [62] BFH 2006–12 195 12 (6.2) 6 PRF1, 2 SH2D1A, 4 STX11, 1 UNCC13D
8 Monoallelic, 4 biallelic or hemizygous
Jing-Shi [61] BFH 2007–14 19 0 (0) 2 PRF1, 1 MUNC 13-4, 1 XLP-1
Wang [34] BFH 2013–14 ND 4 ND
Sieni [57] Italian Registry ND (6 years) ND 11 (ND) 6 PRF1, 2 MUNC 13-4, 2 SH2D1A, 1 MUNC 19-9
10/11 biallelic
Kuriyama [56] Kyushu, Japan 2005–11 ND 1 (ND) 1 PRF1
Gratton [22] MGUH/WRMC 2011–11 1 0 (0) N/A
ND, not described; N/A, not applicable; CCHMC, Cincinnati Children's Hospital Medical Center; WUMC, Washington University Medical Center, U.S.A.; BFH, Beijing Friendship Hospital,
China; MGUH/WRMC, Medstar Georgetown University Hospital/Walter Reed Medical Center U.S.A.
Numbers reported from studies. There may be overlap in cases reported from the same centers.
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studies used a prospectivemethod of patient selection tomake compar-
isons with controls or patients with other diseases in laboratory
parameters such as glycosylated ferritin [40,48], biologically active
free interleukin-18 (IL-18) [36], adenosine deaminase [41] and compar-
ison of cytokine proﬁles between B-cell and T/NK-cell lymphoma-asso-
ciated hemophagocytic syndrome [42]. One study reported that the
sIL2r/ferritin ratio was signiﬁcantly higher in 11 patients with lympho-
ma-associatedHPS compared to 10patientswith benign-disease associ-
ated HLH [63]. A recent study reported a number of abnormalities in the
lymphocyte compartment of 21 patients with HLH. While these abnor-
malities are too varied and non-speciﬁc to assist in diagnosis, they may
have prognostic signiﬁcance [69].3.4. Treatment
Eighteen studies in this review provided detailed descriptions of
treatment and outcomes. Two of these studies were prospective [33,
34]. The remainder were retrospective and included a range of ten to
162 patients (Table 5). Unlike diagnosis, where each study applied
one set of diagnostic criteria to all study participants, treatment was
highly variable both between and within the studies. Among these
studies, all except two used an etoposide-based regimen for at least a
proportion of patients. CHOPwas usedwidely for lymphoma-associated
hemophagocytic syndromes (LAHS); however, 2 studies also used
CHOP therapy outside of the LAHS context, predominantly for EBV-
HLH patients [55,70]. Hematopoietic cell therapy (HCT) was reported
in a small number of patients in seven of these 18 studies [34,44,55,
62,65,70,71].3.4.1. Initial treatment
Initial glucocorticoidswere almost always included in adult treatment
regimens. Beyond this, therewas considerable variation in treatment. The
pattern of practice was ﬁrst and foremost to identify and treat the
underlying cause – infection, malignancy, or autoimmune – with
disease-appropriate therapy and supportive measures, and if necessary,
chemo-immunotherapy. However, there was signiﬁcant variation both
within and among studies in which patients received cytotoxic therapy
such as the etoposide-based HLH-94/2004 treatment protocols or
CHOP. In many cases, particularly in treating MAS, patients considered
corticosteroid-refractory received only a component of the regimen,
such as glucocorticoids and another immunosuppressive drug [13].3.4.2. Etoposide-based Histiocyte Society protocols (HLH-94 and HLH-
2004)
In pediatric HLH, which is rarely associated with an underlying
malignancy, use of etoposide has shown signiﬁcant improvement in sur-
vival if initiated within the ﬁrst 4 weeks of symptoms [72]. This ﬁnding
was replicated in a report of young adults (11 from Kyoto and 9 cases
from the literature) with EBV-associated HLH, wherein treatment with
etoposidewithin 4weeks of presentationwas associatedwith better out-
comes (2 of 7 died) than in thosewho received etoposide after 4weeks or
not at all (12 of 13 died) [55]. In a retrospective study of 162 adults with
HLH, Arca et al. described a trend toward better outcomes when
etoposide was employed (85% vs. 74% survival, p = 0.079) [46]. In con-
trast, Parikh et al. assessed 62 patients with HLH, of whom 20 received
etoposide (9 tumor-associated and 11 non-tumor associated), and
found that the overall survival was similar between the cohorts receiving
etoposide or non-etoposide based regimens [19]. In a retrospective study
of prognostic factors in adult HLH, Li et al. found that etoposide use was
not associated with better outcomes [73].
3.4.3. Other initial therapies
Many patients, particularly in Asia, have been treated with
doxorubicin-based therapy such as CHOP, often in the context of aggres-
sive lymphoma/LAHS (see Table 5). In a retrospective study examining
treatment outcomes with CHOP in 17 adult patients with HLH second-
ary to lymphoma, EBV, or unknown cause, overall response rate was
58.8% (5/7 with lymphoma, 3/5 with EBV, 2/5 with idiopathic HLH)
with 2 year overall survival 43.9% suggesting possible beneﬁt of CHOP
in adult HLH of multiple etiologies [70].
3.4.4. Salvage therapy
The only prospective multicenter study in this review investigated
the effects of a salvage therapeutic regimen in 63 adults who had not
achieved partial response to standard HLH therapy based on the HLH-
94 treatment protocol. The regimen was a hybrid of etoposide- and
doxorubicin-based regimens, consisting of liposomal doxorubicin,
etoposide and pulse methylprednisone (DEP) [34]. Overall response
was 76.2%; however, overall mortality was 54% due to either progres-
sion of underlying disease or recurrence of HLH.
3.4.5. Special populations
Allogeneic HCT in adults has rarely been reported [25]. Chandrakasan
et al. reported on 19 adolescents/adults (age 15–27) with HLH who
received alloHCT at CCMHC and reported overall survival 42.1% (8/19).
Table 5
18 Studies with detailed description of treatment and outcomes.
Reference HPS patients Country HLH treatments provided
Prognostic factors and
outcomes
Arca
Br J Haematol 2015 [46]
Riviere Am J Med 2014 [47]
162 France 42 received HLH-94, 39 etoposide
only, 19 glucocorticoids only, 1 IVIG,
61 no HLH speciﬁc therapy
Etoposide was associated with
a better outcome. Poor
prognostic factors included
age, thrombocytopenia,
lymphoma and no etoposide.
42% overall mortality, 20.4%
30-day morality.
Aulagnon
Am J Kidney Dis 2015 [49]
95 France 69 received etoposide, 33 other
cytotoxic agent, 56 glucocorticoids, 9
IVIG
Early treatment, including
etoposide may be associated
with improved renal function
and survival. Poor prognostic
factors included hematologic
malignancy and AKI stage ≥2.
56% 6 month mortality.
Buyse Intensive Care
Med 2010 [1]
56 ICU patients France 45 received etoposide, 32 other
cytotoxic agent, 31 glucocorticoids, 3
IVIG
Poor prognostic factors
included shock,
thrombocytopenia. B cell
lymphoma, Castleman's
disease associated with
improved survival.
51.8% mortality.
Chandrakasan Biol
Blood Marrow
Transplant 2013 [43]
10 young adult who
underwent allogeneic HCT
United States 10 received HLH-04 and HCT Mortality in young adults
with HLH is higher than
pediatric mortality of 12%
at that center.
50% overall mortality
(44% with RIC)
Chandrakasan ASH
abstract 2013 [44]
19 young adults who
underwent allogeneic HCT
United States 19 received HLH-04 and HCT Mortality in young adults
with HLH is higher than
pediatric mortality of 25%
at the same center.
57.9% overall mortality (43%
with RIC)
Emmenegger Am J
Hematol 2001 [67]
20 patients with MAS Switzerland 20 received IVIG IVIG is effective in MAS if given
early in disease process.
25% mortality.
He International Medical J
2012 [75]
21 China 21 received HLH-04; not clear if any
patients actually received plasma
exchange
The authors speculated that
hemodialysis or
plasmapheresis should be for
patients with ferritin N 1000
ng/mL and LDH N 1000 IU/L to
control hypercytokinemia but
did not present any data to
support this
85.7% mortality.
Imashuku Med Pediatr
Onc 2003 [55]
11 patients with EBV-HLH Japan 4 received HLH-94, 5 etoposide
within 4 weeks of diagnosis, 4 CHOP,
1 other cytotoxic agent, 2 HCT
EBV-HLH patients that
received etoposide by 4 weeks
of diagnosis had a better
prognosis than those treated
late.
72.7% mortality.
Jing-Shi Ann
Hematol 2015 [61]
19 patients with relapsed/
refractory HLH
China 16 received HLH-94, 3 HLH-04, 19
splenectomies
Splenectomy may be effective
in treating patients with
relapsed HLH.
36.8% mortality.
Li Medicine 2014 [73] 103 China 35 received etoposide, 32/49 LAHS
patients received CHOP or other
doxorubicin-based regimens, 83
glucocorticoids, 35 IVIG
Treating underlying
disease, combined with
corticosteroids,
immunosuppressive
therapy and IVIG may
improve prognosis. Poor
prognostic factors included
age, male sex, splenomegaly,
thrombocytopenia.
74.8% mortality,
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Table 5 (continued)
Reference HPS patients Country HLH treatments provided
Prognostic factors and
outcomes
Parikh Mayo Clin Proc 2014
[19]
62 United States 15/32 patients with malignancy 4/6
EBV, 1/3 CMV, 3/5 MAS, 1/7
bacterial/fugal infection, 3/4
idiopathic received etoposide 22
LAHS patients received CHOP
Survival of patients receiving
etoposide-based therapy was
similar to cohort receiving
non-etoposide based
treatment. Worse outcomes in
tumor (including lymphoma)
associated HLH.
30-day mortality 44%, overall
mortality 66%.
Park Ann Hematol 2012
[65]
23 patients with non LAHS (16
EBV, 6 idiopathic, 1 HAV)
South Korea 2 received HLH-94, 11 received
HLH-04, 11 etoposide, 22
glucocorticoids, 5 HCT
No difference in patient
outcomes between group
receiving HLH-94/04 protocol
or other immunosuppressive
regimen. Earlier initiation of
treatment and elevated
ﬁbrinogen were positive
prognostic factors.
73.9% mortality.
Shin J Korean Med
Sci 2008 [70]
17 patients with LAHS,
EBV-HLH or idiopathic
Japan 17 received CHOP, 2 HCT (1 LAHS, 1
EBV-HLH)
CHOP regimen appears to be
effective in both LAHS and
non-LAHS with manageable
adverse effects.
52.9% mortality.
Takahashi Int J Hematol
2001 [71]
52 Japan 25/26 LAHS patients received CHOP, 3
VAHS patients received vincristine,
44 glucocorticoids, 21 IVIG.
Etoposide/HLH-94 not mentioned.
Underlying disease affects
prognosis.
88% LAHS mortality compared
to 11.5% mortality of
non-LAHS patients (VAHS 6%,
BAHS 33%, MAS 0).
Wang Ann Hematol 2013
[33]
40 China 40 received HLH-94, all LAHS
received ECHOP, All MAS treated with
ﬂudarabine + methylprednisone.
20/40 received rhTPO.
rhTPO was associated with
improved platelet count, less
gastrointestinal, pulmonary
and urinary tract bleeding but
had no effect on survival.
35% mortality.
Wang
PLoS ONE
2014 [62]
18/195 HPS patients with
genetic mutations
China 17/18 with mutations received
HLH-94, 5/18 HCT
fHLH is more common than
expected and should be
treated similarly to pediatric
HLH.
39% mortality.
Wang Blood 2015 [34] 63 patients with relapsed/
refractory HPS
China 63 received HLH-94 and DEP, 5
received other cytotoxic. 3 EBV
patients received rituximab. 13 HCT,
7 splenectomies
DEP is an effective salvage
regimen which prolongs
survival in refractory HLH.
54% mortality.
HLH-94/04 (a combination of etoposide, dexamethasone with or without cyclosporine A), IVIG, intravenous immunoglobulin; RIC, reduced intensity conditioning; DEP, liposomal doxo-
rubicin, etoposide,methylprednisone; CHOP (a combination of cyclophosphamide, Adriamycin, vincristine, prednisone); LAHS, lymphoma-associated hemophagocytosis;; EBV-HLH, EBV-
associated HLH; VAHS, virus-associated HLH; BAHS, bacteria-associated HLH; rhTPO, recombinant human thrombopoeitin; HD, hemodialysis; PE, plasma exchange, fHLH, familial HLH;
MAS, macrophage activation syndrome.
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survival was 57% compared to 75% in children b 15 years, p = 0.03 [44].
Other possible treatment modalities discussed in articles included in
this review were IVIG for MAS [67,74], plasma exchange for patients
with serum ferritin ≥ 10,000 μg/L and LDH ≥ 1000 IU/L [75], splenectomy
for relapsed HLH of unknown cause [61], and recombinant human
thrombopoeitin (rhTPO) which improved thrombocytopenia and de-
creased platelet transfusion requirements in a small randomized con-
trolled trial of 40 adults with HLH [33].
3.5. Prognostic factors and outcomes
Outcomes in adultHLHwere heterogeneous; among the 18 studies fo-
cusing on treatment and outcomes,mortality ranged from20.4 to 88%de-
pending on population factors and length of follow up (Table 5). Amongthese studies, the study with the lowest mortality rate only assessed 30-
day mortality in order to limit the impact of underlying disease [46],
whereas the highest mortality rate was in patients with underlying lym-
phoma, which was consistently an adverse prognostic factor [71]. The
largest study, describing 162 patients and all associated HLH conditions,
reported overall mortality 42% [47]. Mortality was generally lowest in au-
toimmune disease patients followed by infection-associated and idio-
pathic HLH patients. Malignancy, particularly lymphoma-associated
HPS/HLH, was a prominent adverse prognostic marker correlating with
poorer survival in multiple large studies [19,46,47,58,73,76]. Patients
with T-cell lymphoma generally had worse outcomes than those with
B-cell lymphoma [76–78]. Other common adverse prognostic factors in-
cluded age N 30 [79], highly elevated ferritin [19,58,79],marked thrombo-
cytopenia [1,46,79], male sex [73], lack of etoposide therapy [46] and low
albumin [19].
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The number of adult HPS/HLH publications has risen dramatically
from less than ten per year in the 1980s to greater than 100 per year
since 2010. Though our inclusion criteria comprises articles from 1975
to current, only one study published prior to 1990 and only 11 articles
published between 1990 to 2000 included 10 or more adult patients.
The dramatic rise in larger studies of adult HPS/HLH in recent years like-
ly reﬂects increased recognition; whether it also indicates a rise in
incidence of HPS/HLH is not clear.
4.1. Diagnosis: established patterns and emerging trends
The Histiocyte Society's pediatric HLH-2004 diagnostic criteria has
been widely extrapolated for use in adults since their publication in
2007. However, these criteria have a number of important shortcomings
in the adult population. First, the molecular diagnosis is applicable only
to those rare cases of adult-onset fHLH, and testing is available only in
specialized centers. Frequency of genetic mutations is inversely
correlated with age of disease onset, with 45% of patients b 1 month
found to have an fHLH mutation compared to 6% of those over age
2 years [26]. Furthermore, part of the rationale of testing children is to
identify patients in whom allogeneic HCT is warranted, but the tolera-
bility and efﬁcacy of HCT in adults, especially older adults is poorly
understood. 12 of 82 studies in this review tested a small proportion
of patients for genetic mutations, which likely reﬂects the lack of access,
high cost, and ill-deﬁned clinical beneﬁt associated with genetic testing
in adults. Thus, the 8 clinical and laboratory features of HLH-2004 are
particularly important in adults, and yet these abnormalities are
relatively non-speciﬁc to HPS/HLH. Extreme hyperferritinemia has
historically been described as nearly pathognomonic for HLH [8,26],
but recent studies have shown that ferritin N 3000 μg/L and even
N50,000 μg/L are very non-speciﬁc in acutely ill adults [64,80].
Hemophagocytosis on bone marrow sampling lacks both sensitivity
and speciﬁcity [17,47,81]. The lack of testing for sIL2r and NK function
identiﬁed in this review is amajor issue in using theHLH-2004 diagnos-
tic criteria in adults. One approach is to simply exclude sIL2r and NK
function from adult diagnostic criteria in favor of other more readily
available parameters common to HPS in adults. For example, in the
HScore for reactive HPS, elevated aspartate transaminase (AST) is in-
cluded but sIL2r and NK function are not. The exclusion of these two
parameters was not on the basis of empiric data. Rather, in the Delphi
study which preceded construction of the HScore, it was judged that
sIL2r, NK function, and CD163 were “not frequently enough assessed
in routine practice” to be included [18,21]. However, HPS is a syndrome
of pathologic immune activation occurring typically in immunocompro-
mised patients and ultimately, sIL2r and NK function are important
objective markers of increased T-cell activity and impaired cytotoxic
function, respectively. sIL2r is a simple, commercially available bio-
chemistry test and most centers with an interest in HPS/HLH should
be able to implement this. NK function may be useful in some adults,
both for diagnosis and conﬁrmation of disease remission, but is more
difﬁcult to implement as the ﬂow cytometry assays require specialized
technicians and reagents.
4.2. Treatment: established patterns and emerging trends
Almost all adult studies describing treatment have been small, retro-
spective and tend to focus on a component of treatment or a subgroup
of HPS/HLH. Glucocorticoids are standard, and for patients where
cytotoxic therapy is thought to be necessary, the etoposide-based
HLH-94 and 2004 protocols and CHOP are commonly used. Optimal
initial therapies, as well as duration of treatment in adults, require
further investigation. For example, the induction phase of the pediatric
HLH-2004 protocol consists of 8 weeks of etoposide-based therapy,
and treatment after that, if required, is intended as a bridge to alloHCT.However, adults treatedwith CHOPwould typically receive CHOP every
3–4weeks for 6–8 cycles (e.g. 18 to 32weeks of chemotherapy). A recent
study evaluating liposomal doxorubicin, etoposide and dexamethasone
(DEP) represents a true milestone in being the ﬁrst prospective, multi
center clinical trial in adults [34]. Establishing standards for initial therapy
remains a pressing need; unlike fHLH, a uniform protocol may not be fea-
sible given the heterogeneity of the underlying/triggering conditions.
Rather, treatment strategies tailored to different associated conditions
(malignancy, infection, or autoimmune) may be needed.
In pediatric HPS/HLH, liberal use of allogeneic HCT is indicated to
replace defective cytotoxic T cells in familial HLH, and sometimes to
treat the underlying disease process, particularly in HPS/HLH associated
with hematologic malignancy. However, the liberal use of allogeneic
HCT described in the HLH-94 and HLH-2004 protocols may not be as ap-
plicable to adults. In the pediatric HLH-94 study, 124/249 patients (50%)
underwent HCT, whereas only 7 of the 18 treatment-focused articles in
this review report transplanting a small number of adults. The low inci-
dence of fHLH, increasedmorbidity of allogeneic HCT in adults compared
to children, relative scarcity of suitable donors, and the poor performance
status and organ function of the relapsed and refractory adult patients are
likely all factors in the low rate of HCT use in adults. Moreover, given the
high prevalence of secondary HPS/HLH in adults driven by elevated cyto-
kine levels froman underlying trigger, HCTwould be unlikely to eradicate
the underlying cause. According to some experts, allogeneic HCT should
be considered on a case-by-case basis in eligible relapsed or refractory pa-
tients as well as the rare adults with late onset familial HLH [25].
5. Areas for future research and conclusions
5.1. Areas for future research
Currently, the paradigm in children is that a largely genetic disease
(fHLH) requires allogeneic HCT in a high proportion of patients. This
review demonstrates that in adults, the vast majority of reported cases
have not been associated with a deﬁned inherited molecular defect.
Early diagnosis is essential, as a proportion of these patients will go on
to develop critical illness, multi-organ failure, and death, and better
diagnostic and prognostic models are needed. Although the HLH-2004
diagnostic criteria are widely used, molecular testing, sIL2r, and NK func-
tion are rarely applied in older patients. Diagnostic and prognostic
models speciﬁc to adults, such as the HScore, have been developed, but
exclude these specialized tests more on the basis of availability than
whether they are actually helpful in diagnosis. The preponderance of sec-
ondary/reactive HPS, combinedwith the lack of speciﬁcity of criteria such
as cytopenias and hyperferritinemia in adults, begs the question of
whether otherwidely availablemarkers of pathologic immune activation
may be useful in diagnosis. The commercial availability of relatively low-
cost sIL2r assays implies that further study of this disease marker should
be conducted in adult HPS/HLH. Promising new biomarkers and thera-
pies in children should be promptly evaluated in adults. For example, in-
terferon gamma has been shown to be a key mediator of the cytopenias
in HLH [82], and the therapeutic potential of an anti-interferon gamma
antibody has shown promise in animal models. A pediatric anti-
interferon gamma antibody phase 1 clinical trial is currently underway
[83]. Another pediatric study of hybrid immunotherapy (anti-thymocyte
globulin, dexamethasone and etoposide, the HIT-HLH trial) [84], is in
progress and the results of this trial, along with the long-awaited HLH-
2004 study results, should inform future studies in adult HLH.
5.2. Concluding remarks
Hemophagocytic syndromes in adults have received increasing at-
tention in the literature over the past 30 years. However, there remains
a paucity of prospectively collected, multi center data, and much of the
diagnosis and treatment in adults is extrapolated from pediatric data. In
children, the disease paradigm has been based on diagnosis of familial
419A. Hayden et al. / Blood Reviews 30 (2016) 411–420HLH and aggressive treatment thereof with cytotoxic therapy and
liberal use of alloHCT. In adults, themajority of studies describe second-
ary HPS associated with acquired immune dysregulation, which may
present with different clinical and laboratory features, requiring differ-
ent diagnostic criteria. The optimal initial therapy and role of alloHCT
require further investigation in adults. Priorities for future research in-
clude development of diagnostic criteria and treatment protocols that
accommodate those disease aspects unique to adults and also rapidly
evaluate and incorporate novel discoveries in pediatric HPS/HLH.
Practice points
• Publications on adult HPS/HLH have increased dramatically in recent
years but the majority are retrospective studies.
• Most studies apply the pediatric Histiocyte Society diagnostic criteria
and treatment protocols, or variants thereof, to adult patients.
• Secondary HPS/HLH is muchmore commonly described than primary
HLH, but adults are rarely tested for genetic abnormalities, soluble
interleukin-2 receptor, or NK function.
• Survival in HLH is heterogeneous andmalignancy/lymphoma- associ-
ated HPS/HLH is associated with poor outcomes.
Research Agenda
• Adult-speciﬁc diagnostic criteria based on commonly evaluable
clinical and laboratory features of secondary HPS/HLH are needed.
• Promising new biomarkers in pediatric HPS/HLH, such as interferon
gamma, should be evaluated in adults.
• Prospective multicenter trials to evaluate treatment and outcomes of
HPS/HLH in adults are needed.
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